At a glance
A coenzyme involved in redox reactions and cellular maintenance.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The source discusses metabolic biology and limited administration studies. Evidence for a precursor or a laboratory pathway should not be assigned directly to NAD+ injections.[1][8][4]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of NAD+.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 500 mg · 1 source tables
Standard / Gradual Titration Approach (3 mL = 166.7 mg/mL)
| Week | Daily Dose (mg) | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 50 mg | 30 units (0.30 mL) |
| Week 2 | 75 mg | 45 units (0.45 mL) |
| Weeks 3–8 | 100 mg | 60 units (0.60 mL) |
| Weeks 9–12 | 100 mg | 60 units (0.60 mL) |
| Weeks 13–16 | 100 mg | 60 units (0.60 mL) |
Frequency: Inject once daily subcutaneously. This gradual titration protocol begins at 50 mg daily to assess tolerance, as starting too high can produce adverse reactions such as insomnia, anxiety, or fatigue[4]. Most individuals find doses in the 50–100 mg range well‑tolerated after ramp‑up[5]. The 3.0 mL dilution keeps per‑injection volumes practical and allows for accurate unit measurements on standard insulin syringes.
Additional schedule context & duration
Concise summary of the once‑daily subcutaneous regimen.
- Goal: Support cellular energy metabolism, DNA repair pathways, and mitochondrial function through exogenous NAD+ supplementation[1].
- Schedule: Daily subcutaneous injections for 8–16 weeks with gradual dose titration.
- Dose Range: 50–100 mg daily; start low (50 mg) and increase by ~25 mg weekly as tolerated.
- Reconstitution: 3.0 mL per 500 mg vial (166.7 mg/mL) for accurate unit measurements.
- Storage: Lyophilized powder frozen at −20 °C (−4 °F); reconstituted solution refrigerated at 2–8 °C (35.6–46.4 °F) for up to 14 days; protect from light.
Suggested daily titration approach for subcutaneous administration.
- Start: 50 mg daily for Week 1 to assess individual tolerance.
- Escalation: Increase by 25 mg in Week 2 (75 mg daily); advance to 100 mg daily by Week 3 if well‑tolerated[4][5].
- Maintenance: Continue at 100 mg daily for Weeks 3–16 (or adjust based on response and tolerability).
- Frequency: Once per day, subcutaneous injection.
- Timing: Any consistent time of day; some users prefer morning administration.
- Site Rotation: Rotate injection sites systematically (abdomen, thighs, upper arms) to prevent tissue buildup.
Read this protocol on Pep Science → · View cited documents ↓
Preparation
Reconstitution Steps
- Allow the lyophilized vial to reach room temperature before opening to minimize moisture condensation.
- Draw 3.0 mL bacteriostatic water (0.9% benzyl alcohol) with a sterile syringe.
- Inject slowly down the vial wall to avoid foaming; do not aim directly at the powder.
- Gently swirl or roll the vial until the powder fully dissolves (do not shake vigorously).
- The resulting solution should be clear and colorless. If discoloration or precipitate appears, discard.
- Label with the reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
- Use within 14 days; inspect before each use for clarity.
Note: Each 0.01 mL (1 unit) contains approximately 1.67 mg of NAD+. Example conversions: 50 mg = 30 units; 75 mg = 45 units; 100 mg = 60 units.
Storage Instructions
Proper storage is critical to preserve NAD+ stability and potency.
- Lyophilized (Unopened): Store at −20 °C (−4 °F) or below (ideally −80 °C for multi‑year storage) in a dry, dark environment[6]. Minimize moisture exposure as NAD+ powder is hygroscopic.
- Reconstituted Solution: Refrigerate at 2–8 °C (35.6–46.4 °F) and use within approximately 14 days[7]. Keep protected from light (UV exposure degrades NAD+).
- Avoid Freeze–Thaw Cycles: Do not repeatedly freeze and thaw reconstituted NAD+ solution, as this reduces potency.
- Inspection: Before each use, inspect the solution for clarity. A fresh NAD+ solution should be clear and colorless. Discard if discoloration, cloudiness, or precipitate develops.
Materials & quantity planning
Source materials checklist · 500 mg
Plan based on an 8–16 week daily protocol with gradual titration as outlined above.
-
Peptide Vials (NAD+, 500 mg each):
- 8 weeks ≈ 11 vials (total 5,075 mg used)
- 12 weeks ≈ 16 vials (total 7,875 mg used)
- 16 weeks ≈ 22 vials (total 10,675 mg used)
-
Insulin Syringes (U‑100, 1 mL):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- 8 weeks (11 vials): 33 mL → 4 × 10 mL bottles
- 12 weeks (16 vials): 48 mL → 5 × 10 mL bottles
- 16 weeks (22 vials): 66 mL → 7 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 500 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 02
- 03
- 07
Source document
Empower Pharmacy — NAD+ injection (lyophilized): compounding specifications and reconstitution guidance (opens in a new tab)www.empowerpharmacy.com
Back to overview ↑ - 09
Source document
AgelessRx — NAD+ injection clinical overview and administration protocols (opens in a new tab)agelessrx.com
Back to overview ↑ - 11
Source document
Pure Bio Labs — NAD+ vial (500 mg): high‑purity peptide product specifications (opens in a new tab)purebiolabs.com
Back to overview ↑ - 15
COMMUNITY · EXTERNAL FORUM
Discuss NAD+ with the community
Explore member conversations and ask questions on glp1chat. Forum posts and listings are not vetted or endorsed by Pep Science, and they are not medical advice or editorial evidence.
Visit the community (opens in a new tab)Continue exploring
Related topics are not interchangeable compounds or formulations.